Stay updated with breaking news from துளைகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
If Wormholes Are Lurking in Our Universe, This Is How We Could Find Them ANDREEA FONT, THE CONVERSATION 15 JANUARY 2021 Albert Einstein s theory of general relativity profoundly changed our thinking about fundamental concepts in physics, such as space and time. But it also left us with some deep mysteries.
One was black holes, which were only unequivocally detected over the past few years. Another was wormholes – bridges connecting different points in spacetime, in theory providing shortcuts for space travellers. Wormholes are still in the realm of the imagination. But some scientists think we will soon be able to find them, too. Over the past few months, several new studies have suggested intriguing ways forward. ....
The Conversation: Wormholes may be lurking in the universe – and new studies are proposing ways of finding them 14 Jan, 2021 12:43 AM 6 minutes to read Could we travel to other universes using wormholes? Photo / 123rf Other By: Andreea Font Albert Einstein s theory of general relativity profoundly changed our thinking about fundamental concepts in physics, such as space and time. But it also left us with some deep mysteries. One was black holes, which were only unequivocally detected over the past few years. Another was wormholes – bridges connecting different points in space-time, in theory providing shortcuts for space travellers. Wormholes are still in the realm of the imagination. But some scientists think we will soon be able to find them, too. Over the past few months, several new studies have suggested intriguing ways forward. ....
Message : Required fields (Reuters) - Swiss drugmaker Novartis paid $650 million to snag an immuno-oncology drug from BeiGene Ltd, the latest Western drugmaker turning to China for must-have assets to fill holes in their cancer portfolios. Novartis Chief Executive Vas Narasimhan s move, which could bring $1.55 billion in milestone payments and royalties for BeiGene, is also an about-face from comments two years ago when he raised data quality and innovation worries as barriers to Big Pharma s Chinese M&A dreams. Novartis will co-develop BeiGene s tislelizumab, an anti-PD-1 antibody similar to Keytruda from Merck and Opdivo from Bristol-Myers Squibb which help the immune system attack cancer and which have reaped billions of dollars in sales. ....